Clinical Considerations of Isavuconazole Administration in High-Risk Hematological Patients: A Single-Center 5-Year Experience
暂无分享,去创建一个
C. van Delden | N. Vernaz | Y. Chalandon | S. Masouridi-Levrat | D. Neofytos | E. Glampedakis | I. Kronig
[1] M. Hoenigl,et al. Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement , 2020, Journal of fungi.
[2] M. Konopleva,et al. Isavuconazole as Primary Anti-Fungal Prophylaxis in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective, Phase II Study. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] G. Papanicolaou,et al. Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm. , 2020, Medical mycology.
[4] Yeon Joo Lee,et al. A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT). , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] B. Noble,et al. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic-cell transplant recipients. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] H. Badali,et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. , 2019, The Lancet. Infectious diseases.
[7] G. Rahav,et al. Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system , 2019, Medical mycology.
[8] D. Kontoyiannis,et al. Defining breakthrough invasive fungal infection–Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology , 2019, Mycoses.
[9] M. Hakki,et al. Isavuconazole to prevent invasive fungal infection in immunocompromised adults: Initial experience at an academic medical centre , 2019, Mycoses.
[10] V. Athans,et al. Real‐world use—Isavuconazole at a large academic medical center , 2019, Mycoses (Berlin).
[11] D. Kontoyiannis,et al. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients , 2018, Mycoses.
[12] D. Kontoyiannis,et al. Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] C. Beigelman-Aubry,et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. , 2018, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[14] P. Kowey,et al. QT Interval Shortening With Isavuconazole: In Vitro and In Vivo Effects on Cardiac Repolarization , 2017, Clinical pharmacology and therapeutics.
[15] D. Denning,et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] J. Perfect,et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. , 2016, The Lancet. Infectious diseases.
[17] J. Baddley,et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial , 2016, The Lancet.
[18] Marisa H Miceli,et al. Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] D. Kontoyiannis,et al. How I treat mucormycosis. , 2011, Blood.
[20] G. Papanicolaou,et al. Hepatic safety of voriconazole after allogeneic hematopoietic stem cell transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[21] J. Perfect,et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.